Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04312243 · ClinicalTrials.gov registry record · Phase 2
NO Prevention of COVID-19 for Healthcare Providers
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT04312243: Clinical Trial Phase 2 study, sponsored by Massachusetts General Hospital.
NCT04312243 is a Phase 2 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04312243, a Phase 2 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
Thousands of healthcare workers have been infected with SARS-CoV-2 and contracted COVID-19 despite their best efforts to prevent contamination. No proven vaccine is available to protect healthcare workers against SARS-CoV-2. This study will enroll 470 healthcare professionals dedicated to care for patients with proven SARS-CoV-2 infection. Subjects will be randomized either in the observational (control) group or in the inhaled nitric oxide group. All personnel will observe measures on strict precaution in accordance with WHO and the CDC regulations.
Interventions
- DRUG Inhaled nitric oxide gas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-04-07 |
| Est. Completion | 2022-01-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04312243
The ClinicalTrials.gov registry entry for NCT04312243 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inhaled nitric oxide gas is the first listed.
NCT04312243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04312243 about?
NCT04312243 is a clinical study titled "NO Prevention of COVID-19 for Healthcare Providers". Thousands of healthcare workers have been infected with SARS-CoV-2 and contracted COVID-19 despite their best efforts to prevent contamination. No proven vaccine is available to protect healthcare workers against SARS-CoV-2. This study will enroll 470 healthcare professionals dedicated to care for ...
What is the current status of trial NCT04312243?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2020-04-07. Estimated completion is 2022-01-10.
What interventions are being tested in trial NCT04312243?
The interventions under investigation include: Inhaled nitric oxide gas (DRUG).
Who is sponsoring clinical trial NCT04312243?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.